Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2021 May 11;325(18):1896-1898.
doi: 10.1001/jama.2021.4388.

Neutralizing Antibodies Against SARS-CoV-2 Variants After Infection and Vaccination

Venkata Viswanadh Edara  1 , William H Hudson  2 , Xuping Xie  3 , Rafi Ahmed  2 , Mehul S Suthar  1
Affiliations
Comparative Study

Neutralizing Antibodies Against SARS-CoV-2 Variants After Infection and Vaccination

Venkata Viswanadh Edara et al. JAMA. .

Abstract

This study examines the neutralizing antibody response to 4 SARS-CoV-2 variants in infected and vaccinated individuals.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: None reported.

Figures

Figure.
Figure.. Neutralizing Antibody Responses Against SARS-CoV-2 Variants
A, Data from 20 patients with acute COVID-19 infection (5-19 days after symptom onset). B, Data from 20 convalescent COVID-19 individuals (32-94 days after symptom onset). C, Data from 14 healthy individuals (aged 18-55 years) who received the Moderna (mRNA-1273) vaccine, 100-μg dose, on day 14 (post–second dose). The geometric mean titers (GMTs) with 95% CI are shown for samples against the A.1, B.1, B.1.1.7, and N501Y variants. The horizontal dashed lines indicate the limit of detection (FRNT50 GMT = 20). Statistical significance was determined with the Kruskal-Wallis test to compare GMTs between the variants, followed by the Dunn’s multiple comparison post hoc test. For A (acutely infected patients) and B (convalescent individuals), no comparisons were statistically significant. For C (vaccinated individuals), significant differences were found for variant A.1 vs B.1 (P < .001), variant A.1 vs B.1.1.7 (P = .02), and variant A.1 vs N501Y (P = .02). FRNT50 indicates live-virus focus reduction neutralization tests with the reciprocal dilution of serum that neutralizes 50% of the input virus.
See this image and copyright information in PMC

References

    1. Suthar MS, Zimmerman MG, Kauffman RC, et al. . Rapid generation of neutralizing antibody responses in COVID-19 patients. Cell Rep Med. 2020;1(3):100040. doi:10.1016/j.xcrm.2020.100040 - DOI - PMC - PubMed
    1. Jackson LA, Anderson EJ, Rouphael NG, et al. ; mRNA-1273 Study Group . An mRNA vaccine against SARS-CoV-2. N Engl J Med. 2020;383(20):1920-1931. doi:10.1056/NEJMoa2022483 - DOI - PMC - PubMed
    1. Dan JM, Mateus J, Kato Y, et al. . Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021;371(6529):eabf4063. doi:10.1126/science.abf4063 - DOI - PMC - PubMed
    1. Widge AT, Rouphael NG, Jackson LA, et al. ; mRNA-1273 Study Group . Durability of responses after SARS-CoV-2 mRNA-1273 vaccination. N Engl J Med. 2021;384(1):80-82. doi:10.1056/NEJMc2032195 - DOI - PMC - PubMed
    1. Liu Y, Liu J, Xia H, et al. . Neutralizing activity of BNT162b2-elicited serum: preliminary report. N Engl J Med. Published online February 17, 2021. doi:10.1056/NEJMc2102017 - DOI - PMC - PubMed

Publication types